Market Overview

Akorn Acquires Betimol® from Santen


today announced that it has acquired the NDA and all rights to Betimol®
(timolol ophthalmic solution) 0.25% & 0.5% from Santen. Akorn plans to
begin shipping Betimol® in the first quarter of 2014.

See full press release

Posted-In: M&A News Guidance Financing Contracts Legal Management Global


Related Articles (AKRX)

View Comments and Join the Discussion!

Chinese Technology ETFs Outperform (QQQC, CQQQ, KWEB)

CareFusion Issues Statement Regarding Government Settlement